MGH

TOMI Environmental Solutions, Inc. Reports Fourth Quarter and Year End 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024
Hydrogen, MGH, Health, Hydrogen peroxide, Sale, Restaurant, Ionization, RELX, International, Webcast, Education, Harvard University, Food industry, GPO, Holiday, Global Biorisk Advisory Council, Academic Medical Center (Amsterdam), Police, Meat, Completion, Transport, Decontamination, Medication, AALAS, American Biological Safety Association, Research, Hospital, Food, ISSA, BIT, CES, Disinfectant, Conference, Horsepower, Growth, Assistant, MIT, Executive, School, Infection, DARPA, Environmental Health (journal), Raymond Castellani, Health care

FREDERICK, Md., April 01, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its fourth quarter and year end 2023 results.

Key Points: 
  • FREDERICK, Md., April 01, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its fourth quarter and year end 2023 results.
  • Financial Results for the year ended December 31, 2023, compared to December 31, 2022
    Total net revenue was $7,355,000 compared to $8,338,000.
  • Financial Results for the three months ended December 31, 2023, compared to December 31, 2022
    Total net revenue was $1,528,000 compared to $2,812,000.
  • TOMI will hold a conference call to discuss Fourth Quarter and year end 2023 results at 4:30 p.m.

Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research

Retrieved on: 
Tuesday, March 26, 2024
MGH, Harvard Medical School, Public health, Mass General Brigham, Massachusetts General Hospital, MDD, Patient, Public, Roche, Research, Merck, Social anxiety disorder, DSM-IV codes, Bristol Myers Squibb, Clinical trial, Neuropsychiatry, HMS, World Health Organization, Therapy, Hospital, Safety, WHO, SAD, Major depressive disorder, PTSD, Mass, Pharmaceutical industry

Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).

Key Points: 
  • Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).
  • “We continue to observe very significant need in the neuropsychiatric patient population,” said Dr. Eric Finzi, Co-Founder of Healis Therapeutics.
  • “MDD remains a public health challenge around the world,” said Erik Van Widenfelt, Head of Clinical Trials at Healis Therapeutics.
  • General Hospital (MGH) and Harvard Medical School,” said Sebastian De Beurs, Co-Founder of Healis Therapeutics.

Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting

Retrieved on: 
Thursday, March 21, 2024
MGH, Eating, Obesity, Oxytocin, Patient, Weight loss, Binge eating disorder, University, Prader–Willi syndrome, Tonix Pharmaceuticals, IND, American Chemical Society, Magnesium, Adolescence, Insulin resistance, Hospital, Safety, ACS, Social anxiety disorder, Spectrum, Pain, Nasal administration, Poster

CHATHAM, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announces a poster presentation at the American Chemistry Society (ACS) Spring 2024 Meeting, held March 17-21, 2024, in New Orleans, Louisiana. A copy of the poster is available under the scientific presentations page of the Tonix website at www.tonixpharma.com.

Key Points: 
  • A copy of the poster is available under the scientific presentations page of the Tonix website at www.tonixpharma.com .
  • The poster presentation titled, Oxytocin Analogs with Enhanced Craniofacial Antinociceptive Effects in Low Magnesium Formulations, describes the discovery and characterization of novel oxytocin analogues that are candidate treatments for craniofacial pain, excessive eating (including Prader Willi Syndrome), and endocrinological conditions including bone health in autism and insulin resistance.
  • “Intranasal oxytocin has several potential therapeutic applications,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • The Phase 2 ‘STROBE’ study at MGH is investigating the efficacy and safety of TNX-1900 as a novel therapeutic agent to reduce binge eating frequency in adults with binge-eating disorder.

Calyxo Announces FDA Clearance for New, Redesigned CVAC System

Retrieved on: 
Tuesday, March 26, 2024
FDA, General Health, Health, Medical Devices, MGH, Kidney, American Urological Association, Urology, Massachusetts General Hospital, Infection, Incidence, SURE, Patient, CVAC, Kidney stone disease, MD, Trial of the century, Dust, Karger Publishers, Vacuum, Pain, Ureteroscopy, Hospital, Medical imaging

Calyxo, Inc. , a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment.

Key Points: 
  • Calyxo, Inc. , a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment.
  • More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback.
  • Based on learnings from over two years of real-world use, Calyxo reimagined its CVAC System to further enhance the SURE procedure.
  • “CVAC” and “Calyxo” are registered trademarks of Calyxo, Inc.

eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient

Retrieved on: 
Thursday, March 21, 2024
Research, Other Health, General Health, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, Pelvic floor dysfunction, MGH, Kidney disease, Gene, Organization, Survival, Massachusetts General Hospital, Transplant, Inflammation, Immunosuppression, Kidney failure, Mortality, Coagulation, Hope, Doctor of Philosophy, Expanded access, Quality of life, Genome, Transgene, Hospital, Kidney, Dialysis, CD40L, Courage, Kidney transplantation, Medicine, Dentistry

eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

Key Points: 
  • eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.
  • Following the procedure, the patient is in good condition and recovering well at MGH.
  • Yet the demand for organs far outpaces supply, with more than 90,000 individuals on the kidney waitlist and approximately 25,000 kidney transplants performed each year.
  • Decades of progress in cross-species transplantation, accelerated by the advancement of modern genome editing tools and next-generation sequencing, have enabled eGenesis to progress genetically engineered organs to the clinical setting.

BostonGene Bolsters Leadership Team to Accelerate Innovation and Growth

Retrieved on: 
Thursday, February 22, 2024
Health, Genetics, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Wake Forest University, Cambia Health Solutions, Senior, Doctor of Philosophy, RingCentral, Small business, Georgetown University, Medical director, Record, Molecular medicine, Drug development, Hospital, Radiology, Beyond Meat, MBA, MGH, Stanford University, University, Pathology, Associate, Patient, Intuit, Goldman Sachs, RPX, Massachusetts General Hospital, Harvard Medical School, Helmy Eltoukhy, Cancer, Management

"On behalf of the BostonGene Board of Directors, I am thrilled to welcome Joe, Mark, and Ned to our team," said Andrew Feinberg, President and CEO of BostonGene.

Key Points: 
  • "On behalf of the BostonGene Board of Directors, I am thrilled to welcome Joe, Mark, and Ned to our team," said Andrew Feinberg, President and CEO of BostonGene.
  • Dr. Lennerz received an MD and a PhD in molecular medicine from the University of Erlangen, Germany.
  • "I am delighted to join BostonGene at such a pivotal moment in its trajectory.
  • In addition to BostonGene, Ned is a board member at RingCentral and Beyond Meat.

bb.q Chicken Teaches Americans to Speak Korean…Fried Chicken in First National Ad Campaign for the Rapidly Growing Franchise

Retrieved on: 
Monday, March 4, 2024
Marketing, Korean fried chicken, Culture, Growth, Language, Millennials, Food, MGH, Internet, Senior, Translation, Meta, Fast food

The new bb.q Chicken ads serve as an invitation for Americans to try the franchise's superior and authentically Korean light, crispy and flavorful fried chicken -- so crispy in fact, it comes through loud and clear in the new YouTube spots. The franchise offers an extensive menu of 14 different flavor options, created with marinades delivered directly from Seoul and served on boneless and bone-in options. Other fan favorites at bb.q are K-food offerings, such as ddeok-bokki and kimchi fried rice.

Key Points: 
  • The franchise offers an extensive menu of 14 different flavor options, created with marinades delivered directly from Seoul and served on boneless and bone-in options.
  • The new bb.q Chicken ad campaign launched on March 1, reaching potential customers for more than 250 North American bb.q locations.
  • The ads were created by full-service marketing agency MGH , which managed all creative and media buying for the campaign.
  • It was for this reason that bb.q Chicken launched a campaign with an educational tone.

MelliCell Announces Dr. Fatima Cody Stanford as New Advisory Board Member

Retrieved on: 
Tuesday, February 27, 2024
Diabetes, FAAP, Obesity, FAHA, Hospital, MPA, MBA, DSM-IV codes, MGH, FACP, Human, CNN, PBS, Associate, HMS, Pediatrics, Massachusetts General Hospital, Harvard Medical School, Adipose tissue, Research, Public

This strategic move aligns with MelliCell's mission to revolutionize the treatment and understanding of metabolic diseases through advanced fat cell research.

Key Points: 
  • This strategic move aligns with MelliCell's mission to revolutionize the treatment and understanding of metabolic diseases through advanced fat cell research.
  • Dr. Stanford brings to MelliCell a rich legacy of expertise in obesity medicine as an Associate Professor of Medicine and Pediatrics at Massachusetts General Hospital (MGH) / Harvard Medical School (HMS).
  • As MelliCell prepares for its upcoming funding round, the addition of Dr. Stanford to the advisory board marks a pivotal moment in the company's trajectory towards establishing new standards in metabolic disease treatment.
  • "Joining MelliCell's dynamic team is an exciting opportunity to advance the fight against obesity through our focused research on adipose tissue," expressed Dr. Stanford.

Discoverer of the Klotho Gene and Pioneer in Longevity and Disease Prevention Dr. Makoto Kuro-o Joins Scientific Advisory Board of ADvantage Therapeutics

Retrieved on: 
Monday, February 5, 2024
Endocrinology, Ageing, Medical school, Nephrology, Health, Genetics, Dean (education), MGH, FAU, Science, Research, Florida Atlantic University, Patient, Fibroblast, HHS, BOCA, Jichi Medical University, Entrepreneurship, University, Harvard Medical School, Therapy, General partnership, Disease, Thiel Fellowship, Former, Biology, MIT, Blueprint, Molecular biology, Conference, Pharmaceutical industry

Kuro-o and Madden will speak at the invite-only Entrepreneurship, Longevity, and Biotech Conference in Boca Raton on February 9 and 10.

Key Points: 
  • Kuro-o and Madden will speak at the invite-only Entrepreneurship, Longevity, and Biotech Conference in Boca Raton on February 9 and 10.
  • The conference assembles biotech and longevity scientists and entrepreneurs to share research and exchange ideas for improving the biotech and longevity industries.
  • He discovered and named the klotho gene in 1997, and since then has written and published extensively on the topic.
  • His pioneering research has opened new and promising paths toward understanding longevity as well as preventing and treating disease.

Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, January 16, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Senior, Patient, Internal medicine, MGH, Harvard Medical School, Rett syndrome, DSM-IV codes, Neuropsychiatry, Harvard College, Central nervous system, Hospital, Teva Pharmaceuticals, Massachusetts General Hospital, Gene editing, Inc., Pharmaceutical industry

Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Julie Jordan, M.D., as Chief Medical Officer.

Key Points: 
  • Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Julie Jordan, M.D., as Chief Medical Officer.
  • She most recently served as Chief Medical Officer of Homology Medicines, a clinical-stage company advancing gene therapies for the treatment of rare diseases.
  • “A proven leader with deep clinical and regulatory expertise to advance pioneering medicines through development, we are thrilled to welcome Julie to the team,” said Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene.
  • Prior to assuming her role as Chief Medical Officer, Dr. Jordan served as the company’s Senior Vice President, Head of Clinical Development and Operations.